Epstein-Barr virus: new targets for vaccine design and treatment
A lab generated monoclonal antibody prevented EBV infection and EBV lymphomas in rodent models and could have future clinical applications.
List view / Grid view
A lab generated monoclonal antibody prevented EBV infection and EBV lymphomas in rodent models and could have future clinical applications.
The new findings could lead to a therapeutic target for immune-related disorders, like multiple sclerosis.
Results from an in vivo CRISPR knockout screen, targeting genes involved in autophagy, could lead to new therapies.
Scientists have reported a promising technique, based on somatic cell nuclear transfer, to treat infertility.
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.
A new study shows that changes in clonal dominance characterises T-cell memory against multiple COVID-19 variants following mRNA vaccinations.
Understanding heart changes at the molecular level during early infection with adenovirus could enable identification of those at higher risk of arrhythmia.
Researchers discover that fusion proteins and a gene regulatory protein complex interact through disordered domains.
Proteins regulating plasminogen-plasmin levels can be used to identify patients at risk of progressing to a severe stage of COVID-19.
Researchers have developed an algorithm which could improve diagnostics of ovarian high-grade serous carcinoma.
Researchers find that the RAD51 protein prevents genomic duplications that could arise from reactivated origins.
The potential for brain organoids to develop consciousness is a key issue in neuroscience, which has prompted new ethical considerations.
The study's findings could be applied to the development of new vaccine and therapeutic strategies for influenza.
Researchers find that an overgrowth of nerve cells in the bladder could cause rUTIs, which may offer new approaches to manage symptoms.
Treatment with Palbociclib and a compound targeting CAD increased survival to 100 percent for selected lymphoma cell lines.